Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

NCT03477539 PHASE2 COMPLETED Results posted

This phase II trial studies how well daratumumab works in treating transplant-eligible patients with multiple myeloma. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.

Details

Lead sponsor	Mayo Clinic
Phase	PHASE2
Status	COMPLETED
Enrolment	49
Start date	Mon Apr 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Mar 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Plasma Cell Myeloma

Interventions

• Autologous Hematopoietic Stem Cell Transplantation
• Daratumumab
• Lenalidomide

Countries

United States